{
  "abstract": "Objective: Osteoarthritis (OA) is a leading cause of disability, yet no licensed therapies can prevent or slow its progression. We aimed to identify potential disease-modifying OA drug (DMOAD) targets by integrating genetic and differential protein abundance (DPA) evidence.\n\nMethod: We evaluated genetically predicted perturbations of plasma protein levels using cis-protein quantitative trait loci (cis-pQTLs) across three European cohorts (UK Biobank Pharma Proteomics Project, deCODE, and Fenland) and outcome data from the Genetics of Osteoarthritis Consortium across 11 OA phenotypes. Following limit-of-detection and missingness filtering, DPA evaluated 2133 proteins in 7186 prevalent OA cases and 29,584 controls from UK Biobank. MR-prioritised proteins were further assessed using summary-data-based Mendelian randomisation (SMR) with OA joint-tissue eQTL data, alongside pathway, protein-interaction, and druggability analyses.\n\nResults: Cis-MR and colocalisation prioritised 81 proteins, of which 30 showed joint-tissue transcriptomic support in SMR analyses. DPA identified 1436 proteins associated with ≥1 OA phenotype, of which 1314 (91.5%) retained significance in sensitivity analyses. Seventeen proteins had matched MR and DPA support, including three Tier 1 druggable targets (DLK1, SOST, and TNFRSF9); seven of these had SMR support. EHBP1, LGALS3, and OGN showed concordant DPA and MR effects and cross-platform evidence. EHBP1, PCSK7 and ITIH4 emerged as under-recognised candidates. Pathway analyses recapitulated established OA processes, while drug enrichment identified hypothesis-generating compounds.\n\nConclusion: Integration of cis-MR, colocalisation, DPA, and tissue-specific transcriptomic evidence prioritised several potential OA therapeutic targets. DLK1, LGALS3, OGN and EHBP1 emerged as high-priority candidates, while EHBP1, PCSK7 and ITIH4 represent under-recognised candidates warranting functional investigation.",
  "abstract_shown": true,
  "affiliations": [
    "Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK",
    "Centre for Rheumatic Diseases, King's College London, London, UK",
    "Faculty of Medicine, KU Leuven, Leuven, Belgium",
    "Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA",
    "Centre for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA",
    "Centre for Genetics and Genomics Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK",
    "NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK",
    "Department of Medicine, Harvard Medical School, Boston, MA, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Weijie Liu"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Benjamin P. Zuckerman"
    },
    {
      "affs": [
        2,
        3,
        4
      ],
      "name": "Art Schuermans"
    },
    {
      "affs": [
        5,
        6
      ],
      "name": "Gisela Orozco"
    },
    {
      "affs": [
        3,
        4,
        7
      ],
      "name": "Michael C. Honigberg"
    },
    {
      "affs": [
        5,
        6
      ],
      "name": "John Bowes"
    },
    {
      "affs": [
        0,
        6
      ],
      "name": "Terence W. O'Neill"
    },
    {
      "affs": [
        0,
        6
      ],
      "name": "Sizheng Steven Zhao"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1pczweqn8ghre.bib",
  "cited_by": 0,
  "doi": "10.1016/j.ocarto.2026.100890",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757520/",
  "id": "1pczweqn8ghre",
  "issns": [
    "2665-9131"
  ],
  "landing_url": "https://doi.org/10.1016/j.ocarto.2026.100890",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "ORIGINAL PAPER"
    ],
    [
      "openalex",
      "2745|Osteoarthritis Treatment and Mechanisms"
    ]
  ],
  "openalex": "W7223466729",
  "pdf_url": null,
  "pmcid": "PMC13757520",
  "pmid": "43022691",
  "published": "2026-10-24",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/1pczweqn8ghre.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:08Z",
      "native_id": "PMC13757520",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.ocarto.2026.100890"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2745|Osteoarthritis Treatment and Mechanisms",
      "subfield": "general"
    }
  ],
  "title": "Genetically informed search for potential osteoarthritis drug targets across the proteome",
  "title_text": "Genetically informed search for potential osteoarthritis drug targets across the proteome",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:08Z",
  "url": "https://research.draconitic.com/paper/1pczweqn8ghre",
  "venue": "Osteoarthritis and Cartilage Open",
  "versions": []
}